10
3
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T40051 | Acid Ceramidase-IN-1 | ||
Acid Ceramidase-IN-1 is a highly effective and orally bioavailable inhibitor of acid ceramidase (AC, ASAH-1), with an inhibitory concentration (IC50) of 0.166 μM. Additionally, Acid Ceramidase-IN-1 exhibits exceptional b... | |||
T75142 | Acid Ceramidase-IN-2 | ||
Acid Ceramidase-IN-2 (compound 1), an acid ceramidase inhibitor, exhibits potentially antiproliferative and cytostatic effects. This compound is of interest due to the overexpression of human acid ceramidase in prostate ... | |||
T21658 | ARN14974 | Others | |
ARN14974 is a benzoxazolone carboxamide. ARN14974 is a potent inhibitor of acid ceramidase with IC50 of 79 nM[1]. | |||
T1307 | Carmofur | HCFU | Nucleoside Antimetabolite/Analog , Virus Protease , SARS-CoV , DNA/RNA Synthesis |
Carmofur (HCFU) is a highly potent acid ceramidase inhibitor, used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy. | |||
T68441 | SABRAC | ||
SABRAC inhibits acid ceramidase in PC3 MC metastatic prostate cancer cells (IC50 = <1 µM), as well as induces accumulation of ceramides in the same cells. | |||
T37056 | D-erythro-MAPP | ||
D-erythro-MAPP is a derivative of ceramide and an inhibitor of alkaline ceramidase (Ki = 2-13 μM; IC50 = 1-5 μM). It is selective for alkaline ceramidase over acid ceramidase (IC50 = >500 μM) as well as the serine/threon... | |||
T11835L | LCL521 dihydrochloride | 1,3DMG-B13 dihydrochloride | Others |
LCL521 dihydrochloride is a compound that functions as an inhibitor of both acid ceramidase (ACDase) and lysosomal acid sphingomyelinase (ASMase). | |||
T36468 | ARN14988 | ||
ARN14988 is a potent inhibitor of acid ceramidase (IC50 = 12.8 nM for the human enzyme). It inhibits acid ceramidase activity and increases levels of C16 dihydro ceramide and C16 ceramide in A375, G361, M14, MeWo, MNT-1,... | |||
T11835 | LCL521 | Others , Phospholipase | |
LCL521 inhibits lysosomal acid sphingomyelinase (ASMase).LCL521 is an acid ceramidase (ACDase) inhibitor. | |||
T22069 | D-NMAPPD | ||
D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates the properties of NMDA receptor by enhancing the endogenous production of ceramides. D-NMAPPD has anticancer effecs [1] [2]. |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-00880 | ASAH1 Protein, Human, Recombinant (His & SUMO) | Human | E. coli |
ASAH1 Protein, Human, Recombinant (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 58.7 kDa and the accession number is Q13510. | |||
TMPH-02490 | ASAH1 Protein, Mouse, Recombinant (GST & His & Myc) | Mouse | E. coli |
ASAH1 Protein, Mouse, Recombinant (GST & His & Myc) is expressed in E. coli expression system with N-10XHis-GST and C-Myc tag. The predicted molecular weight is 43.8 kDa and the accession number is Q9WV54. | |||
TMPY-05099 | GBA/glucocerebrosidase Protein, Human, Recombinant (His) | Human | HEK293 Cells |
Mutations in the GBA gene, encoding the lysosomal hydrolase glucocerebrosidase (GCase), are the most common known genetic risk factor for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). ASAH1 (acid ceramida... |